Evaluation of the efficacy of Oncotype DX for prostate cancer

Evaluation of the efficacy of Oncotype DX for prostate cancer - ODX for PC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029563

Enrollment

Registered

2017-10-16

Start date

2017-08-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) over 50 years old men 2) AS (active surveillance) is appropriate 3) Histology (biopsy) prove low risk prostate cancer (T1-2, N0 , M0, Gleason score<=6, PSA<=10 ng/ml) 4) Having provided voluntary written consent for participation in this study

Exclusion criteria

Exclusion criteria: 1) Patients whose laboratory data is not sufficient. 2) Patients judged by investigators ineligible.

Design outcomes

Primary

Measure	Time frame
Oncotype DX in addition to conventional evaluation for low risk prostate cancer correctly predict their prognosis.	—

Countries

Japan

Contacts

Public ContactSatoru Maruyama

Hokkaido University Graduate School of Medicine Department of Genito-Urinary Surgery

smaru@med.hokudai.ac.jp011-706-5966

Outcome results